links for 2009-05-08
-
An editorial accompanying a new cost-efficacy study in the same issue of the journal found that the addition of ixabepilone to capecitabine (Xeloda) adds about $31,000 to the overall medical costs of metastatic breast cancer while providing about 1 more month of "quality-adjusted" survival.